Payload Information
General Information of This Payload
| Payload ID | PAY0AKUNH |
|||||
|---|---|---|---|---|---|---|
| Name | AZ13599185 |
|||||
| Synonyms |
AZ13599185
Click to Show/Hide
|
|||||
| Target | Microtubule (MT) | |||||
| Structure |
|
|||||
| Formula | C40H62N6O7S |
|||||
| Isosmiles | CCC(C)C(NC(=O)C1CC(C)CCN1C)C(=O)N(CC)C(CC(OC(C)=O)c1nc(C(=O)NC(Cc2ccc(N)cc2)CC(C)C(=O)O)cs1)C(C)C |
|||||
| InChI |
InChI=1S/C40H62N6O7S/c1-10-25(6)35(44-37(49)33-18-24(5)16-17-45(33)9)39(50)46(11-2)32(23(3)4)21-34(53-27(8)47)38-43-31(22-54-38)36(48)42-30(19-26(7)40(51)52)20-28-12-14-29(41)15-13-28/h12-15,22-26,30,32-35H,10-11,16-21,41H2,1-9H3,(H,42,48)(H,44,49)(H,51,52)
|
|||||
| InChIKey |
XGSFLELSPQDOPW-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
771.038 |
Polar area |
184.26 |
||
Complexity |
54 |
xlogp Value |
5.3058 |
|||
Heavy Count |
54 |
Rot Bonds |
19 |
|||
Hbond acc |
10 |
Hbond Donor |
4 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 0.62 | nM |
HCT 116 cells
|
Colon cancer
|
[1] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 0.71 | nM |
DU145 cells
|
Prostate carcinoma
|
[1] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1.14 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
[1] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
MEDI4276 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligibility requires HER2+ advanced breast/gastric cancer patients (age≥18) with prior HER2-targeted therapy and measurable disease (RECIST 1.1), excluding recent anticancer treatment (<28 days), excessive anthracycline exposure, or active brain metastases.
|
||||
| Administration Dosage |
Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02576548 | Phase Status | PHASE1 | ||
| Clinical Description |
A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include safety assessment (AEs/SAEs/DLTs) to determine MTD, with monitoring through 90 days post-MEDI4276 dose, covering lab tests, vital signs, and ECGs for comprehensive safety profile evaluation.
|
||||
| Other Endpoint |
Secondary objectives evaluate efficacy (ORR/PFS/OS over 3 years) and PK/immunogenicity (Cmax/AUC/ADA incidence within 30 days post-treatment), measuring tumor response and drug exposure while tracking antibody development.
|
||||
References